➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
McKesson
Boehringer Ingelheim
Colorcon

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 8,580,264

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,580,264
Title:Subcutaneously administered anti-IL-6 receptor antibody
Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
Inventor(s): Zhang; Xiaoping (Wayne, NJ), Bao; Min (San Mateo, CA), Jahreis; Angelika M. (Menlo Park, CA), Terao; Kimio (Funabashi, JP)
Assignee: Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:13/290,366
Patent Claims:see list of patent claims

Details for Patent 8,580,264

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) 2030-11-08 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) 2030-11-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 001 2010-01-08   Start Trial Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) 2030-11-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 002 2010-01-08   Start Trial Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) 2030-11-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 003 2010-01-08   Start Trial Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) 2030-11-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) 2030-11-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
McKinsey
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.